HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Coppertone Recalls Benzene-Tainted Sunscreens; Cosmetics Regulatory & Legal News

Executive Summary

Consumers can contact Coppertone for refunds for aerosol sunscreens found to contain benzene, a human carcinogen that should not adversely affect users at levels detected, the Beiersdorf brand says. More cosmetics regulatory and legal news in brief.

You may also be interested in...



P&G Recalls Secret, Old Spice Sprays For Benzene Contamination As Class Actions Mount Around US

There’s an increasingly familiar pattern to leading personal-care manufacturers’ benzene troubles in the states: Independent testing lab Valisure flags their product(s) as contaminated with the carcinogen; class actions file in federal courts; and, frequently, recalls are undertaken “out of an abundance of caution.”

Valisure’s Findings Of Benzene In Body Sprays Suggest Ongoing Aerosol Propellant Problem

Hydrocarbon-based propellants can harbor trace levels of benzene, among other impurities, when quality controls are insufficient. Leading brands’ antiperspirant and deodorant body sprays are the latest aerosol personal-care products identified by independent laboratory Valisure as contaminated with the carcinogen.

FDA’s Proposed Order For Sunscreens, A First Under OTC Reforms, Reprises 2019 Proposed Rule

As anticipated, the US FDA’s proposed order for sunscreens released on 24 September creates a bridge to the agency’s 2019 proposed rule before the CARES Act overhauled OTC drug review in March 2020.

Related Content

Topics

UsernamePublicRestriction

Register

RS151810

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel